This is a working overview of GLP-1 receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-27. Anything still debated is marked as such rather than presented as settled.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Clinical studies have reported notable reductions in body weight among participants. Early trials measured safety and explored several dose levels, and later studies tracked body-weight change over months of treatment. Investigators also monitor effects on glycemic markers, liver fat, and blood lipids. Because the compound is still in development, questions about long-term safety, cardiovascular outcomes, and durability after treatment ends remain open.
The three-receptor design places retatrutide in a distinct category relative to older incretin-based therapies. Single agonists target one receptor, and dual agonists target two. Adding a third target broadens the pharmacological footprint and introduces new trade-offs among efficacy, tolerability, and glucose control. How these trade-offs resolve in large trials is a central focus of current research.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (solid) | -20 °C or below | Freezer storage with desiccant |
| Solubility | Soluble in water and aqueous buffer | Careful dissolution needed at higher concentrations |
| Appearance | White to off-white lyophilised powder | Visual inspection for discolouration |
| Primary analytical method | Reversed-phase HPLC with UV detection | Paired with mass spectrometry for identity |
| Common synonyms | Triple-agonist peptide; GLP-1/GIP/glucagon agonist | Naming varies across the literature |
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
== Portrayals in television == Television is in over 90% of U.S. households and in 1995 it had a strong influence on how viewers perceive the world. In terms of mental illness portrayals, television has been a pioneer in representing these illnesses across thousands of programs in nearly a century's worth of content. The media often depicts people with mental illness as violent or unpredictable, creating misrepresentations and harmful stereotypes. Research shows that viewers who watch more television are more likely to have negative views about mental health. Although television has frequently misrepresented mental health, there has been a growing shift towards more accurate and honest portrayals.
== Treatment == The treatment of burn scar contracture and deformity begins upon hospitalization. Wound care and functional outcomes can be predicted from the initial assessment of wound depth and location. Epidermal and partial thickness wounds heal in 1 to 3 weeks through epithelial migration from the wound edges and epithelial budding from the appendages of the sweat and hair glands. These wounds pose only a small risk of contracture and hypertrophic scarring. Full-thickness (FT) injuries cause dermal wound healing, which is characterized by maturation (contraction and increased tensile strength), proliferation (collagen synthesis leading to wound closure), and inflammation (edema). FT wounds heal by excision and grafting, contracture, or epithelial ingrowths from the margins. Because of insufficient tissue length and extensibility, severe damage to the integument system may result in significant impairment and disability. By using stress-strain curves, where stress is equal to force and strain is equal to tissue elongation, mechanical engineering principles can be used to assess the biomechanics of skin and scars. Stretching an adult burn scar is similar to stretching a tendon in terms of elasticity. On the other hand, persistent force applied to tissue will cause it to elongate, which will lead to a plastic change in length and an increase in range of motion. Fast and forceful stress is much less effective than a gentle, prolonged stretch that the patient can tolerate.
=== Sanger sequencing === Sanger sequencing recently was used to evaluate the enrichment of mutant DNA from a mixture of 1:20 mutant:wildtype DNA. The variant DNA containing a mutation was obtained from a breast cancer cell line known to contain p53 mutations. Comparison of Sanger sequencing chromatograms indicated that the mutant allele was enriched 13 fold when COLD-PCR was used compared to traditional PCR alone. This was determined by the size of the peaks on the chromatogram at the variant allele location. As well, COLD-PCR was used to detect p53 mutations from lung-adenocarcinoma samples. The study was able to detect 8 low level (under 20% abundance) mutations that would likely have been missed using conventional methods that don't enrich for variant sequence DNA.
is the molar latent heat of melting. In most substances, the volume increases when melting occurs, so the melting temperature increases with pressure. However, because ice is less dense than water, the melting temperature decreases. In glaciers, pressure melting can occur under sufficiently thick volumes of ice, resulting in subglacial lakes. The Clausius-Clapeyron relation also applies to the boiling point, but with the liquid/gas transition the vapor phase has a much lower density than the liquid phase, so the boiling point increases with pressure. Water can remain in a liquid state at high temperatures in the deep ocean or underground. For example, temperatures exceed 205 °C (401 °F) in Old Faithful, a geyser in Yellowstone National Park. In hydrothermal vents, the temperature can exceed 400 °C (752 °F). At sea level, the boiling point of water is 100 °C (212 °F). As atmospheric pressure decreases with altitude, the boiling point decreases by 1 °C every 274 meters. High-altitude cooking takes longer than sea-level cooking. For example, at 1,524 metres (5,000 ft), cooking time must be increased by a fourth to achieve the desired result. Conversely, a pressure cooker can be used to decrease cooking times by raising the boiling temperature. In a vacuum, water will boil at room temperature.
All sport in South Africa under apartheid was segregated by race, with separate clubs and governing bodies. Only white bodies were affiliated to the South African Olympic and Empire [later Commonwealth] Games Association (SAOEGA, later SAOCGA) so only white South Africans competed at the Olympic Games and the Empire (later Commonwealth) Games. The IOC under Avery Brundage regarded this as an internal matter for South Africa, and, committed to keeping politics and sports separate, took no action. From 1948, black athletes and their federations complained to the IOC about their exclusion, but were told to take the matter up with the SAOCGA. In the 1950s, NOCs from the Eastern Bloc led by the Soviet Union began to question this stance. With the decolonisation of Africa from the late 1950s, NOCs from newly independent states opposed to apartheid began affiliating to the IOC. However, the IOC itself was not representative of NOCs but rather a group of co-opted individuals, still mostly from First World countries. On the other hand, the international federations (IFs), the governing bodies of the Olympic sports, were quicker to give a voice to newer members.
Sources: en.wikipedia.org
=== Neuroscience's findings === Neuroscience and brain imaging have shown increasing potential for helping science understand happiness and sadness, as parts of the brain have been identified as having a role in the control of happiness, specifically with regard to research in the field of neurotransmitters. Though it may be impossible to achieve any comprehensive objective measure of happiness, some physiological correlates to happiness can be measured. Stefan Klein, in his book The Science of Happiness, links the dynamics of neurobiological systems (i.e., dopaminergic, opiate) to the concepts and findings of positive psychology and social psychology. Nobel Prize winner Eric Kandel and researcher Cynthia Fu described very accurate diagnoses of depression just by looking at fMRI brain scans. By identifying neural correlates for emotions, scientists may be able to use methods like brain scans to tell us more about the different ways of being "happy". Richard Davidson has conducted research to determine which parts of the brain are involved in positive emotions. He found that the left prefrontal cortex is more activated when we are happy and is also associated with greater ability to recover from negative emotions as well as enhanced ability to suppress negative emotions. Davidson found that people can train themselves to increase activation in this area of their brains. It is thought that our brain can change throughout our lives as a result of our experiences; this is known as neuroplasticity.
== Application of SPME in forensic science == SPME has become an essential technique in forensic science, particularly for analyzing complex matrices such as blood, urine, and environmental samples. Its advantages include the ability to perform rapid and sensitive extractions without the need for extensive sample preparation, which is crucial in forensic investigations where sample integrity is paramount. For instance, SPME has been successfully employed to detect drugs of abuse, explosives, and other volatile compounds from various samples, allowing for the efficient identification of substances relevant to criminal cases. The automation and miniaturization of SPME techniques further enhance their applicability in forensic settings, enabling high-throughput analysis and reducing the risk of contamination.
The most common response was the possibility of a Metabolic Myopathy that translates to a metabolic muscle illness and are usually caused by the muscle's inability to breakdown nutrients. The muscles begin to break themselves down to yield energy. As Angel gets closer to possibly having a diagnosis, she starts to think about a possible future with children. She worries that if her disease is genetic, she wouldn't want to put her children at risk. A medical student from Italy reaches out to Dr. Sanders. She describes her 4th- year thesis on metabolic gene testing that could be beneficial in narrowing down a diagnosis. Angel travels to Turin, Italy for blood and urine testing. The testing showed that Angel had a normal metabolic gene profile, which eliminated many possible metabolic disorders. The physicians in Italy submitted her genomes into a sequencing trial that could take up to two months to process but could hopefully result with a diagnosis. After the two months, Angel receives a call from the Physician with a complete result and a solid diagnosis of Carnitine Palmitoyltransferase II Deficiency.
About 89 percent of the bank's $172 billion in deposit liabilities exceeded the maximum insured by the FDIC. Two days after the failure, the FDIC received exceptional authority from the Treasury and announced jointly with other agencies that all depositors would have full access to their funds the next morning. Seeking to auction off all or parts of the bank, the FDIC reopened it on Monday March 13 as a newly organized bridge bank, Silicon Valley Bridge Bank, N.A. Although some characterized the government response as a bailout, the plan did not entail rescuing the bank, its management or shareholders, but rather making uninsured depositors whole from the proceeds of selling the bank's assets, without the use of taxpayer money. The collapse of SVB had significant consequences for startup companies in the U.S. and abroad, with many briefly unable to withdraw money from the bank. Other large technology companies, media companies, and wineries were also affected. For a number of founders and their venture capital backers, this was the bank of choice.
Sources: en.wikipedia.org
== Limitations == Although the Ka/Ks ratio is a good indicator of selective pressure at the sequence level, evolutionary change can often take place in the regulatory region of a gene which affects the level, timing or location of gene expression. Ka/Ks analysis will not detect such change. It will only calculate selective pressure within protein coding regions. In addition, selection that does not cause differences at an amino acid level—for instance, balancing selection—cannot be detected by these techniques. Another issue is that heterogeneity within a gene can make a result hard to interpret. For example, if Ka/Ks = 1, it could be due to relaxed selection, or to a chimera of positive and purifying selection at the locus. A solution to this limitation would be to apply Ka/Ks analysis across many species at individual codons. The Ka/Ks method requires a rather strong signal in order to detect selection. In order to detect selection between lineages, then the selection, averaged over all sites in the sequence, must produce a Ka/Ks greater than one—quite a feat if regions of the gene are strongly conserved. In order to detect selection at specific sites, then the Ka/Ks ratio must be greater than one when averaged over all included lineages at that site—implying that the site must be under selective pressure in all sampled lineages. This limitation can be moderated by allowing the Ka/Ks rate to take multiple values across sites and across lineages; the inclusion of more lineages also increases the power of a sites-based approach.
In 1869, when Dmitri Mendeleev published his periodic table, the space under iodine was empty; after Niels Bohr established the physical basis of the classification of chemical elements, it was suggested that the fifth halogen belonged there. Before its officially recognized discovery, it was called "eka-iodine" (from Sanskrit eka 'one') to imply it was one space under iodine (in the same manner as eka-silicon, eka-boron, and others). Scientists tried to find it in nature; given its extreme rarity, these attempts resulted in several false discoveries. The first claimed discovery of eka-iodine was made by Fred Allison and his associates at the Alabama Polytechnic Institute (now Auburn University) in 1931. The discoverers named element 85 "alabamine", and assigned it the symbol Ab, designations that were used for a few years. In 1934, H. G. MacPherson of University of California, Berkeley disproved Allison's method and the validity of his discovery. There was another claim in 1937, by the chemist Rajendralal De. Working in Dacca in British India (now Dhaka in Bangladesh), he chose the name "dakin" for element 85, which he claimed to have isolated as the thorium series equivalent of radium F (polonium-210) in the radium series. The properties he reported for dakin do not correspond to those of astatine, and astatine's radioactivity would have prevented him from handling it in the quantities he claimed. Moreover, astatine is not found in the thorium series, and the true identity of dakin is not known.
== Treatment eligibility == Many providers use informed consent, whereby someone seeking hormone therapy can sign a statement of informed consent and begin treatment without much gatekeeping. For other providers, eligibility is determined using major diagnostic tools such as ICD-11 or the Diagnostic and Statistical Manual of Mental Disorders (DSM) to classify a patient with gender dysphoria. The Endocrine Society requires physicians that diagnose gender dysphoria and gender incongruence to be trained in psychiatric disorders with competency in ICD-11 and DSM-5. The healthcare provider should also obtain a thorough assessment of the patient's mental health and identify potential psychosocial factors that can affect therapy.
Sources: en.wikipedia.org
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.
Cool, dry conditions with desiccant are standard for the solid form. Long-term storage is usually at freezer temperatures, with short-term handling at refrigerator temperature. Vials are allowed to equilibrate before opening to prevent condensation.
Lipid conjugation increases hydrophobicity, which shifts chromatographic retention and can broaden peaks. It also creates additional related species when acylation is incomplete or the chain is oxidised. Methods are therefore developed to separate acylated and non-acylated forms explicitly.
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.